280 related articles for article (PubMed ID: 28303362)
21. Preoperative systemic and intraperitoneal chemotherapy consisting of S-1, cisplatin and docetaxel in patients with marginally resectable gastric cancer.
Kurokawa Y; Hamakawa T; Miyazaki Y; Takahashi T; Yamasaki M; Miyata H; Nakajima K; Takiguchi S; Mori M; Doki Y
Anticancer Res; 2015 Apr; 35(4):2223-8. PubMed ID: 25862882
[TBL] [Abstract][Full Text] [Related]
22. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics.
Morgan RJ; Doroshow JH; Synold T; Lim D; Shibata S; Margolin K; Schwarz R; Leong L; Somlo G; Twardowski P; Yen Y; Chow W; Lin P; Paz B; Chu D; Frankel P; Stalter S
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5896-901. PubMed ID: 14676112
[TBL] [Abstract][Full Text] [Related]
23. Docetaxel, cisplatin and S-1 (DCS) combination chemotherapy for gastric cancer patients with peritoneal metastasis: a retrospective study.
Ohnuma H; Sato Y; Hirakawa M; Kikuchi S; Miyanishi K; Sagawa T; Takahashi Y; Nobuoka T; Okamoto K; Miyamoto H; Takemasa I; Takayama T; Kato J
Cancer Chemother Pharmacol; 2018 Mar; 81(3):539-548. PubMed ID: 29383482
[TBL] [Abstract][Full Text] [Related]
24. A Prospective Phase I/II Study of Docetaxel, Cisplatin and Continuous Capecitabine in Advanced Oesophago-Gastric Cancer (NWCOG-3).
Gollins S; Massalha S; Mullard A; Williams RM; Lloyd A; Morris J; Garcia-Alonso A
Clin Oncol (R Coll Radiol); 2018 Jul; 30(7):409-417. PubMed ID: 29573846
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer.
Kim TW; Kang YK; Ahn JH; Chang HM; Yook JH; Oh ST; Kim BS; Lee JS
Ann Oncol; 2002 Dec; 13(12):1893-8. PubMed ID: 12453857
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer.
Park KW; Ahn JS; Park YS; Lee J; Kang JH; Park JO; Lim HY; Im YH; Kang WK; Park K; Lee SI
Cancer Chemother Pharmacol; 2007 Jan; 59(1):17-21. PubMed ID: 16721549
[TBL] [Abstract][Full Text] [Related]
27. Phase I Study of Axitinib in Combination with Cisplatin and Capecitabine in Patients with Previously Untreated Advanced Gastric Cancer.
Oh DY; Doi T; Shirao K; Lee KW; Park SR; Chen Y; Yang L; Valota O; Bang YJ
Cancer Res Treat; 2015 Oct; 47(4):687-96. PubMed ID: 25687867
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of intraperitoneal and intravenous chemotherapy for advanced gastric cancer with peritoneal metastasis.
Chen Y; Wang XJ; Lin RB; Chen L; Lin G; Guo ZQ
Tumori; 2014; 100(5):e180-8. PubMed ID: 25343556
[TBL] [Abstract][Full Text] [Related]
29. Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer.
Lee KW; Park SR; Oh DY; Park YI; Khosravan R; Lin X; Lee SY; Roh EJ; Valota O; Lechuga MJ; Bang YJ
Invest New Drugs; 2013 Dec; 31(6):1547-58. PubMed ID: 24091982
[TBL] [Abstract][Full Text] [Related]
30. Phase II trial of capecitabine plus modified cisplatin (mXP) as first-line therapy in Japanese patients with metastatic gastric cancer (KSCC1104).
Satake H; Iwatsuki M; Uenosono Y; Shiraishi T; Tanioka H; Saeki H; Sugimachi K; Kitagawa D; Shimokawa M; Oki E; Emi Y; Kakeji Y; Tsuji A; Akagi Y; Natsugoe S; Baba H; Maehara Y;
Cancer Chemother Pharmacol; 2017 Jan; 79(1):147-153. PubMed ID: 27942930
[TBL] [Abstract][Full Text] [Related]
31. Multi-center Randomized Phase II Study of Weekly Docetaxel Versus Weekly Docetaxel-plus-Oxaliplatin as a Second-line Chemotherapy for Patients with Advanced Gastric Cancer.
Kim JY; Ryoo HM; Bae SH; Kang BW; Chae YS; Yoon S; Baek JH; Kim MK; Lee KH; Lee SA; Song HS; Kim JG
Anticancer Res; 2015 Jun; 35(6):3531-6. PubMed ID: 26026121
[TBL] [Abstract][Full Text] [Related]
32. Vorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer: phase II study and biomarker analysis.
Yoo C; Ryu MH; Na YS; Ryoo BY; Lee CW; Kang YK
Br J Cancer; 2016 May; 114(11):1185-90. PubMed ID: 27172248
[TBL] [Abstract][Full Text] [Related]
33. Multicenter phase II study of capecitabine plus cisplatin as first-line therapy for human epidermal growth factor receptor 2-negative advanced gastric cancer: Yokohama Clinical Oncology Group Study YCOG1107.
Sato K; Kunisaki C; Kosaka T; Takagawa R; Takahashi M; Izumisawa Y; Miyamoto H; Sato S; Tanaka Y; Yamaguchi N; Kimura J; Ono HA; Makino H; Akiyama H; Endo I
Cancer Chemother Pharmacol; 2017 Nov; 80(5):939-943. PubMed ID: 28913549
[TBL] [Abstract][Full Text] [Related]
34. A multicenter, phase I dose-escalating study of docetaxel, cisplatin and S-1 for advanced gastric cancer (KDOG0601).
Nakayama N; Koizumi W; Sasaki T; Higuchi K; Tanabe S; Nishimura K; Katada C; Nakatani K; Takagi S; Saigenji K
Oncology; 2008; 75(1-2):1-7. PubMed ID: 18719348
[TBL] [Abstract][Full Text] [Related]
35. Phase II study of first-line biweekly docetaxel and cisplatin combination chemotherapy in advanced gastric cancer.
Quintero-Aldana G; Jorge M; Grande C; Salgado M; Gallardo E; Varela S; López C; Villanueva MJ; Fernández A; Alvarez E; González P; Castellanos J; Casal J; López R; Campos Balea B
Cancer Chemother Pharmacol; 2015 Oct; 76(4):731-7. PubMed ID: 26242221
[TBL] [Abstract][Full Text] [Related]
36. Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial.
Ochenduszko S; Puskulluoglu M; Konopka K; Fijorek K; Urbanczyk K; Budzynski A; Matlok M; Lazar A; Sinczak-Kuta A; Pedziwiatr M; Krzemieniecki K
Med Oncol; 2015 Oct; 32(10):242. PubMed ID: 26354521
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of capecitabine plus cisplatin in patients with gastric cancer.
Salah-Eldin MA; Ebrahim MA; AL-Ashry MS
Anticancer Drugs; 2009 Mar; 20(3):191-6. PubMed ID: 19396018
[TBL] [Abstract][Full Text] [Related]
38. Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: a double-blind randomised phase 3 study.
Kim ST; Kang JH; Lee J; Park SH; Park JO; Park YS; Lim HY; Hwang IG; Lee SC; Park KW; Lee HR; Kang WK
Eur J Cancer; 2014 Nov; 50(16):2822-30. PubMed ID: 25218337
[TBL] [Abstract][Full Text] [Related]
39. Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction.
Deenen MJ; Meulendijks D; Boot H; Legdeur MC; Beijnen JH; Schellens JH; Cats A
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1285-95. PubMed ID: 26499900
[TBL] [Abstract][Full Text] [Related]
40. Phase I/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis.
Fushida S; Kinoshita J; Kaji M; Hirono Y; Goda F; Yagi Y; Oyama K; Sudo Y; Watanabe Y; Fujimura T;
Cancer Chemother Pharmacol; 2013 May; 71(5):1265-72. PubMed ID: 23423490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
